Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma

• Published in: Oncotarget Vol. 8; no. 13; pp. 22203 - 22217
• Main Authors: Cai, Yi, Dodhia, Sonam, Su, Gloria H
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 28.03.2017
• Subjects: Animals; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - enzymology; Carcinoma, Squamous Cell - pathology; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - enzymology; Head and Neck Neoplasms - pathology; Humans; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases - antagonists & inhibitors; Protein Kinase Inhibitors - therapeutic use; Review; Signal Transduction - drug effects; PI3K signaling; PI3K inhibitor; PIK3CA mutation; head and neck squamous cell carcinoma; personalized medicine
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.14729

The phosphoinositide 3-kinase (PI3K) signaling pathway is the most commonly mutated pathway in head and neck squamous cell carcinoma (HNSCC). There are several drugs targeting members of the PI3K signaling pathway in development for HNSCC. In this article, we review the genetic alterations reported in the pathway pertinent to HNSCC, various agents in development targeting various mediators of the pathway, results from clinical trials, and remaining challenges in the development of PI3K pathway inhibitors.